Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Climb Bio, Inc. (CLYM)
USD13.21
-0.79 (-5.64%)
US NASDAQ Healthcare Biotechnology
Address
PMB #117, 2801 Centerville Road 19808-1609
Wellesley Hills, DE, US
Wellesley Hills, DE, US
CEO
Aoife Brennan BCh MMSc
Website
eliemtx.com
IPO
2021-08-10
CIK 1768446 ISIN US28658R1068
Also trades on
NASDAQ Global Market · CLYM (USD)
NASDAQ Global Market · ELYM (USD)
Description
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD13.21
-0.79 (-5.64%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.10
Float Shares
59.86M
Free Float %
87.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.86% | +6.22% | +2.42% | +57.58% | +281.33% | +186.00% | +793.75% | +46.10% | +46.10% | +46.10% | +46.10% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
13.21
Low
17.00
+28.7%
Consensus
21.67
+64.0%
Median
20.00
+51.4%
High
35.00
+165.0%
DCF (Unlevered)
0.49
-96.3%
DCF (Levered)
0.52
-96.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 13 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
27.50
+108.2%
|
| Last Quarter | 8 |
21.25
+60.9%
|
| Last Year | 10 |
20.60
+55.9%
|
| All Time | 10 |
20.60
+55.9%
|
Quality scores
Altman Z-Score
99.88
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+42.5% ★ Q1'26: +35.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-99.9% Q1'26: -140.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+40.8% Q1'26: +1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 EPS Ana. |
Dec 2027 11 Rev. Ana. 11 EPS Ana. |
Dec 2028 12 EPS Ana. |
Dec 2029 11 Rev. Ana. 10 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
888.9K
888.9K – 888.9K
|
—
— – —
-100.0% YoY
|
2.53M
2.53M – 2.53M
|
57.27M
57.27M – 57.27M
+2,161.2% YoY
|
| EBITDA |
-30.36M
|
-59.75M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-30.36M
|
-59.85M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-73.90M
est: -75.62M (+2.3%)
|
-59.85M
est: -56.24M (-6.4%)
|
-62.93M
-77.77M – -46.53M
-11.9% YoY
|
-86.00M
-92.15M – -54.39M
-36.7% YoY
|
-131.38M
-211.50M – -63.72M
-52.8% YoY
|
-125.28M
-125.28M – -125.28M
+4.6% YoY
|
-131.69M
-131.69M – -131.69M
-5.1% YoY
|
| SGA |
16.03M
|
21.17M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.53
est: -1.57 (+2.5%)
|
-0.88
est: -0.82 (-7.4%)
|
-0.87
-1.15 – -0.69
-6.5% YoY
|
-1.05
-1.36 – -0.80
-20.1% YoY
|
-1.44
-3.12 – -0.94
-37.8% YoY
|
-1.85
-1.85 – -1.85
-28.0% YoY
|
-1.94
-1.94 – -1.94
-5.1% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-06-11 | BTIG | Buy | Buy | Maintain |
| 2026-06-08 | BTIG | Buy | Buy | Maintain |
| 2026-05-12 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-05-08 | Wedbush | Outperform | Outperform | Maintain |
| 2026-05-06 | BTIG | Buy | Buy | Maintain |
| 2026-04-21 | Oppenheimer | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-06-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-06-10 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-06-09 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-06-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-06-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-06-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-06-03 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-06-02 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-06-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
1
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
2.11M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+2,106,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Pre-Funded Warrants (Right to Buy) | 2,106,000 | 0.00 | 210.60 | 22,546,000 | I | ↗ |
| 2026-02-26 | Thomas Stephen Basil | Director | S-Sale | D | Common Stock | 16,313 | 7.01 | 114.3K | 154,657 | D | ↗ |
| 2026-02-25 | Thomas Stephen Basil | Director | S-Sale | D | Common Stock | 33,687 | 7.00 | 236.0K | 170,970 | D | ↗ |
| 2026-02-13 | Thomas Stephen Basil | Director | S-Sale | D | Common Stock | 10,000 | 5.81 | 58.1K | 204,657 | D | ↗ |
| 2026-02-12 | Thomas Stephen Basil | Director | S-Sale | D | Common Stock | 90,000 | 5.23 | 471.0K | 214,657 | D | ↗ |
| 2026-01-06 | Wilson Perrin Megan | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 3.81 | 1.14M | 300,000 | D | ↗ |
| 2026-01-06 | Driscoll Cindy | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 3.81 | 381.0K | 100,000 | D | ↗ |
| 2026-01-06 | Brennan Aoife | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 700,000 | 3.81 | 2.67M | 700,000 | D | ↗ |
| 2026-01-06 | ALTSCHULLER Susan | Officer | A-Award | A | Stock Option (Right to Buy) | 142,500 | 3.81 | 542.9K | 142,500 | D | ↗ |
| 2026-01-05 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 7,111 | 3.50 | 24.9K | 3,403,429 | I | ↗ |
| 2025-12-12 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 101,462 | 2.86 | 290.2K | 3,396,318 | I | ↗ |
| 2025-12-11 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | D-Return | D | Common Stock | 20,440,000 | 0.00 | — | 3,081,757 | I | ↗ |
| 2025-10-01 | ALTSCHULLER Susan | Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 1.97 | 1.18M | 600,000 | D | ↗ |
| 2025-08-07 | Thomas Stephen Basil | Director | A-Award | A | Common Stock | 100,375 | 0.00 | — | 304,657 | D | ↗ |
| 2025-06-30 | Brennan Aoife | Director / Officer | S-Sale | D | Common Stock | 20,618 | 1.22 | 25.2K | 48,132 | D | ↗ |
| 2025-06-27 | Thomas Stephen Basil | Director | M-Exempt | A | Common Stock | 25,094 | 0.00 | — | 204,282 | D | ↗ |
| 2025-06-27 | Brennan Aoife | Director / Officer | M-Exempt | D | Restricted Stock Units | 68,750 | 0.00 | — | 206,250 | D | ↗ |
| 2025-06-20 | Pimblett Emily | Officer | S-Sale | D | Common Stock | 1,242 | 1.24 | 1.5K | 18,888 | D | ↗ |
| 2025-06-18 | Pimblett Emily | Officer | M-Exempt | D | Restricted Stock Units | 5,000 | 0.00 | — | 15,000 | D | ↗ |
| 2025-06-17 | Wilson Perrin Megan | Officer | — | — | Stock Option (Right to Buy) | 600,000 | 1.58 | 948.0K | 0 | D | ↗ |
| 2025-06-17 | Driscoll Cindy | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 1.20 | 240.0K | 200,000 | D | ↗ |
| 2025-06-04 | WILLIAMS DOUGLAS E | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.29 | 51.6K | 40,000 | D | ↗ |
| 2025-06-04 | Thomas Stephen Basil | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.29 | 51.6K | 40,000 | D | ↗ |
| 2025-06-04 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.29 | 51.6K | 40,000 | I | ↗ |
| 2025-06-04 | Levin Andrew David | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.29 | 51.6K | 40,000 | D | ↗ |
| 2025-06-04 | Dunn Judith | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.29 | 51.6K | 40,000 | D | ↗ |
| 2025-06-04 | Drapkin Kimberlee C | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.29 | 51.6K | 40,000 | D | ↗ |
| 2025-06-04 | Cumbo Alexander | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.29 | 51.6K | 40,000 | D | ↗ |
| 2025-03-31 | WILLIAMS DOUGLAS E | Director | A-Award | A | Stock Option (Right to Buy) | 78,873 | 1.22 | 96.2K | 78,873 | D | ↗ |
| 2025-03-28 | Drapkin Kimberlee C | Director | A-Award | A | Stock Option (Right to Buy) | 80,000 | 1.28 | 102.4K | 80,000 | D | ↗ |
| 2025-03-28 | Cumbo Alexander | Director | A-Award | A | Stock Option (Right to Buy) | 80,000 | 1.28 | 102.4K | 80,000 | D | ↗ |
| 2025-03-27 | Thomas Stephen Basil | Director | M-Exempt | D | Restricted Stock Units | 25,093 | 0.00 | — | 25,094 | D | ↗ |
| 2025-03-20 | Pimblett Emily | Officer | S-Sale | D | Common Stock | 1,199 | 1.31 | 1.6K | 15,130 | D | ↗ |
| 2025-03-18 | Pimblett Emily | Officer | M-Exempt | D | Restricted Stock Units | 5,000 | 0.00 | — | 20,000 | D | ↗ |
| 2025-01-13 | Pimblett Emily | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 1.92 | 192.0K | 100,000 | D | ↗ |
| 2025-01-13 | Kaplan Brett | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.92 | 960.0K | 500,000 | D | ↗ |
| 2025-01-13 | Brennan Aoife | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,150,000 | 1.92 | 2.21M | 1,150,000 | D | ↗ |
| 2025-01-01 | Thomas Stephen Basil | Director | M-Exempt | A | Common Stock | 50,188 | 0.00 | — | 154,095 | D | ↗ |
| 2024-12-19 | Pimblett Emily | Officer | S-Sale | D | Common Stock | 1,235 | 2.02 | 2.5K | 11,329 | D | ↗ |
| 2024-12-18 | Pimblett Emily | Officer | M-Exempt | D | Restricted Stock Units | 5,000 | 0.00 | — | 25,000 | D | ↗ |
| 2024-11-11 | WILLIAMS DOUGLAS E | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 4.06 | 81.2K | 20,000 | D | ↗ |
| 2024-11-08 | WILLIAMS DOUGLAS E | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
68.18M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aoife Brennan BCh MMSc | Chief Executive Officer, President & Director | 1M | — |
| Perrin Wilson | Chief Business Officer | 793.4K | — |
| Susan Altschuller | CFO & Principal Accounting Officer | 570.8K | — |
| Cindy J. Driscoll | Senior VP of Finance & Principal Accounting Officer | — | female |
| Edgar D. Charles | Chief Medical Officer | — | — |
| Janaki Subramanyam | Vice President & Head of Regulatory Affairs | — | female |
| Adam Villa | Senior Vice President of Technical Operations | — | male |
| Theresa Donegan | Vice President & Head of Quality | — | female |
| Ashley Jones | Senior VP of People & Workforce Strategy | — | female |
| Chandra Adams | VP, General Counsel & Secretary | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CLYM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
